Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Polar Capital Global Healthcare Lags Behind Benchmark In First Half

Fri, 10th May 2019 09:36

LONDON (Alliance News) - Polar Capital Global Healthcare Trust PLC said on Friday it lagged against its benchmark for the first half of its financial year, as the healthcare trust underperformed in the period.

For the six months to the end of March, the trust's net asset value negative return was 3.0%, compared to the 2.3% negative return by the MSCI ACWI/Healthcare Index in sterling terms, with dividends reinvested.

Net asset value per share as at March 31 was 233.53 pence, up from 183.00p the same date the year before, but down from 241.91p at the end of September.

Polar Capital's share price at the end of March was 216.00p, reflecting a discount to net asset value of 7.5%, widened from 6.1% the year before.

Shares in Polar Capital Global Healthcare were down 1.0% on the day Friday at 203.50 pence, having fallen 5.8% since the period-end.

The trust said that the overall healthcare market "modestly underperformed", with major sell-offs in October and December due to trade friction, slowing global growth, as well as political uncertainties.

Detractors within the trust's portfolio includes Diurnal Group PLC, which reported that its congenital adrenal hyperplasia treatment product Chronocort failed to meet its primary objective in its phase three trial.

Another detractor was Consort Medical PLC, due to delays in some of its customer projects.

However, stocks that performed well were Merck & Co Inc, with strong momentum in its immuno-oncology and vaccines businesses, and Renalytix AI PLC, due to progress in the development of its AI-enabled product for treating kidney diseases.

"While backward looking, the temperamental, almost nervous nature of the market further underpins our view that large-cap healthcare companies should be a relatively attractive place to invest in the near to medium term," Polar Capital Global Healthcare said.

"With technology at the fore, we continue to believe we can find companies within our investment universe that are capable of delivering mid to high single-digit, organic, top-line growth, operating leverage as well as high single to low double-digit total shareholder returns," the trust added.

More News
11 May 2020 13:07

UK EXECUTIVE CHANGE SUMMARY: Abcam Board Confirms Support For Chair

UK EXECUTIVE CHANGE SUMMARY: Abcam Board Confirms Support For Chair

Read more
15 Apr 2020 14:32

UK TRADING UPDATE SUMMARY: Kromek To Make 2,000 Ventilators For UK

UK TRADING UPDATE SUMMARY: Kromek To Make 2,000 Ventilators For UK

Read more
1 Apr 2020 14:47

Diurnal Gets European Marketing Authorisation For Chronocort

Diurnal Gets European Marketing Authorisation For Chronocort

Read more
6 Mar 2020 17:12

UPDATE: Diurnal Placing Raises GBP11 Million For Drug Development

UPDATE: Diurnal Placing Raises GBP11 Million For Drug Development

Read more
6 Mar 2020 12:40

Diurnal Announces GBP7 Million Placing To Fund Drug Development

Diurnal Announces GBP7 Million Placing To Fund Drug Development

Read more
6 Mar 2020 10:07

Diurnal raises at least ?7m through conditional placing

(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced a conditional placing with institutional investors on Friday, to raise at least ?7m before expenses, at a price of 32p per new share.

Read more
5 Mar 2020 17:21

Diurnal Group Names Director Sam Williams Interim Chair

Diurnal Group Names Director Sam Williams Interim Chair

Read more
13 Feb 2020 13:07

Diurnal Says US FDA Accepts New Drug Application For Alkindi Sprinkle

Diurnal Says US FDA Accepts New Drug Application For Alkindi Sprinkle

Read more
13 Feb 2020 09:47

Diurnal clears FDA hurdle for 'Alkindi Sprinkle'

(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Thursday that its new drug application (NDA) for 'Alkindi', or hydrocortisone granules in capsules for opening and to be known in the US as 'Alkindi Sprinkle', has been accepted for review by the US Food and Drug Administration (FDA).

Read more
11 Feb 2020 13:45

Diurnal narrows loss as it progresses drugs to market

(Sharecast News) - Speciality pharmaceutical company Diurnal Group narrowed its first-half loss by 53% to ?4.6m, it announced on Tuesday, which it said reflected improved revenues and a reduction in clinical development expenses for the period.

Read more
11 Feb 2020 09:20

Diurnal Loss Narrows In First Half Amid Improved Sales Of Alkindi

Diurnal Loss Narrows In First Half Amid Improved Sales Of Alkindi

Read more
4 Feb 2020 15:54

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
20 Jan 2020 11:17

Diurnal In Good Health Ahead Of Second Half Amid Alkindi Progress

Diurnal In Good Health Ahead Of Second Half Amid Alkindi Progress

Read more
16 Dec 2019 13:20

Diurnal Submits Market Authorisation Application For Chronocort

Diurnal Submits Market Authorisation Application For Chronocort

Read more
2 Dec 2019 14:40

Diurnal Submits New Drug Application For Aklindi Sprinkle In US

Diurnal Submits New Drug Application For Aklindi Sprinkle In US

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.